FierceBiotech Dec 17, 2025 Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road
FierceBiotech Dec 17, 2025 Norgine gets in on Vir's hepatitis D program with €550 European licensing pact
FierceBiotech Dec 17, 2025 Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay
FierceBiotech Dec 17, 2025 Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst
FierceBiotech Dec 17, 2025 Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team
FierceBiotech Dec 17, 2025 Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B
FierceBiotech Dec 17, 2025 Medtronic rolls out new peripheral thrombectomy system while making advances in brain bleeds
FierceBiotech Dec 17, 2025 Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’
FierceBiotech Dec 16, 2025 December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B
FierceBiotech Dec 16, 2025 Xoma acquires another struggling biotech, this time zeroing in on Generation Bio
FierceBiotech Dec 16, 2025 Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
FierceBiotech Dec 16, 2025 Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug
FierceBiotech Dec 16, 2025 Sanofi signs $1B biobucks pact for Alzheimer’s asset in 2nd biotech deal of the day